Compare Gilead Sciences, Inc. (GILD) vs SMX Security Matters plc (SMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs SMX Security Matters plc — how do they compare? Gilead Sciences, Inc. trades at $136.99 (market cap $168.35B), while SMX Security Matters plc trades at $16.21 (market cap $17.04M). The key difference: Gilead Sciences, Inc. is far larger — about 9879.7× SMX Security Matters plc's market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while SMX Security Matters plc pays none. Which is the better fit depends on your goals.
| GILD | SMX | |
|---|---|---|
Market Cap | $168.35B | $17.04M |
Sector | Health | Technology |
52-Week High | $155.80 | $103.71K |
52-Week Low | $110.56 | $12.87 |
Enterprise Value | $191.42B | -$14.29M |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.06, down slightly by 0.11% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 8% year-over-year, beating estimates, though a net loss of $6.75 per share resulted from acquisition-related costs. Analyst consensus is strongly bullish with a $151.22 price target, and recent news highlights robust HIV drug sales and pipeline progress.
The outlook for GILD is positive, driven by raised 2026 guidance and HIV franchise strength, but risks include patent cliffs by the mid-2030s and integration challenges from acquisitions. Investors should weigh the high valuation multiples against growth potential, with the stock offering upside if execution continues to exceed expectations.
SMX trades at $15.77, down 0.19% with a bearish technical signal from moving averages. The company reported significant losses with -$169.18M net income for 2025 and negative ROE of -819.22%, though recent news highlights balance sheet strengthening and commercialization progress in recycled plastics traceability. Cash flow remains dependent on financing activities.
Outlook remains challenged by persistent losses and negative profitability metrics, offset by positioning in the growing recycled plastics verification market. Key risks include execution on commercialization and cash burn. Institutional sentiment appears mixed amid fundamental weakness but potential regulatory tailwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About SMX Security Matters plc
SMX Security Matters plc is a digital authentication and tracking technology company that uses a chemical-based, invisible marker system to trace and verify products across global supply chains. Their technology creates a 'digital twin' of physical products, used for quality control, counterfeiting prevention, and ensuring sustainability compliance from raw materials to final sale. The company's solutions are applied across various industries, including precious materials, luxury goods, and fast-moving consumer goods.
Read more on SMX →
